Application of interferon regulatory factor 4 (irf4) gene in coronary atherosclerotic heart disease

A technology for coronary atherosclerosis and regulatory factors, applied in the field of gene function and application, can solve the problems of inability to effectively and completely repair myocardial tissue, cardiac insufficiency, arrhythmia, etc., and achieve the degree of inhibition of myocardial hypertrophy and fibrosis. , The effect of increasing cardiac infarct size and protecting cardiac function

Active Publication Date: 2015-09-30
WUHAN UNIV
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

After myocardial infarction, only a small number of myocardial cells divide and proliferate, unable to effectively and completely repair myocardial tissue. Therefore, the myocardium in the infarcted area can only be replaced by scar tissue without contractile function through fibrous tissue hyperplasia, thereby causing severe arrhythmia, Heart failure or even death

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of interferon regulatory factor 4 (irf4) gene in coronary atherosclerotic heart disease
  • Application of interferon regulatory factor 4 (irf4) gene in coronary atherosclerotic heart disease
  • Application of interferon regulatory factor 4 (irf4) gene in coronary atherosclerotic heart disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] [Example 1] Myocardial infarction (MI) model acquisition

[0041] 1. Grouping of experimental animals: male C57BL / 6 strain a-MHC-Cre mice (a-MHC-Cre), IRF4 knockout mice (KO), heart-specific IRF4 transgenic mice (TG) and non-transgenic mice Mice (NTG), the myocardial infarction (MI) model was induced by ligation of the left anterior descending coronary artery (LAD) of the mouse heart. Randomly divided into 8 groups, each group: C57BL / 6 strain a-MHC-Cre mice sham operation group (a-MHC-Cre SHAM) and MI operation group (a-MHC-Cre MI), IRF4 gene knockout mice Sham operation group (KO SHAM) and MI operation group (KO MI), non-transgenic mouse sham operation group (NTG SHAM) and MI operation group (NTG MI), heart-specific IRF4 transgenic mouse sham operation group (TG SHAM) And MI surgery group (TG MI).

[0042] 2. The MI model uses blocking the left anterior descending coronary artery (LAD) of the mouse heart to cause myocardial infarction. The operation process of the mode...

Embodiment 2

[0051] [Example 2] Myocardial infarction size, myocardial hypertrophy and fibrosis detection in mouse myocardial infarction (MI) model

[0052] 1. Collect materials

[0053] (1) Preliminary work: prepare a urine cup filled with 20mL of 10% formaldehyde in advance, and label it (mouse number, group, type of operation and date of collection). Place the petri dish filled with 10% KCl solution at the sampling site. Turn on the analytical balance, adjust to zero, and then weigh and kill the mice.

[0054] (2) Material collection: Ophthalmic curved forceps clamped the vascular pedicle below the atrial appendage, cut off the heart, and quickly placed it in 10% KCl solution. After the heart stops beating in the diastolic phase, place it on sterilized gauze, gently squeeze the fluid in the heart cavity, dip the surface fluid dry, weigh and record, put the heart into the corresponding urine cup, fix it for 48 hours and use it for pathological testing.

[0055] (3) Relevant measureme...

Embodiment 3

[0074] [Example 3] Cardiac function detection in myocardial infarction (MI) model mice

[0075] 1 Ultrasound detection of cardiac function

[0076] 1.1 Preliminary preparation

[0077] (1) Anesthesia machine preparation: first connect the oxygen cylinder and the air inlet port on the anesthesia machine, then unscrew the sealing cap of the dosing port on the anesthesia machine, quickly add isoflurane to the safety scale, and then tighten the sealing cap. Unscrew the main valve on the oxygen cylinder, adjust the knob of the flow control valve, and maintain the outlet pressure at 0.2-0.3mPa.

[0078] (2) Preparation of the mice to be tested: After the mice to be tested were quickly anesthetized with isoflurane, the hair on the left chest area was shaved, and the head of the treated mice was inserted into the anesthetic catheter sleeve, and treated with 1.5-2.0% isoflurane Alkane maintains a stable anesthesia in mice.

[0079] 1.2 Cardiac function test

[0080] The mice were p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of interferon regulatory factor 4 (IRF4) gene in coronary atherosclerotic heart disease, belonging to the field of gene functions and applications. According to the application, IRF4 gene knockout mice and heart-specific IRF4 transgenic mice are taken as experimental subjects, and myocardial infarction model is constructed by blocking mouse heart left anterior descending coronary artery (LAD); results show that compared with a-MHC-Cre moue, the myocardial infarction area, myocardial hypertrophy and myocardial fibrosis degree of the IRF4 gene knockout mouse are remarkably increased, while the heart function of the heart-specific IRF4 transgenic mouse is remarkably improved. Therefore, the function of IRF4 gene in coronary atherosclerotic heart disease is mainly reflected in the protective effect of IRF4 gene on coronary atherosclerotic heart disease. Relative to the function of IRF4, the invention provides application of IRF4 in preparation of medicaments for treating coronary atherosclerotic heart disease.

Description

technical field [0001] The invention belongs to the field of gene function and application, more specifically the invention relates to the application of interferon regulatory factor 4 (Interferon Regulatory Factor 4, IRF4) in coronary atherosclerotic heart disease. Background technique [0002] Myocardial infarction (MI) is myocardial necrosis caused by acute and persistent coronary ischemia and hypoxia, and is a common type of ischemic heart disease. Cardiomyocytes will die due to ischemia, which is one of the common diseases that seriously threaten human health and life. In recent years, the morbidity and mortality of coronary heart disease have gradually increased. "China Cardiovascular Disease Report 2005" is the first authoritative report on China's cardiovascular disease released by my country, revealing that the prevalence of hypertension, dyslipidemia, obesity, and diabetes in my country is increasing year by year, and the above diseases are the risk of coronary hea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K48/00A61K38/17A61P9/00A61P9/10
Inventor 李红良刘小熊张晓东张艳蒋丁胜万埝
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap